Amneal says interim Phase 4 ELEVATE-PD data show Crexont adds about 3 hours daily “Good On” time in Parkinson’s patients

Amneal Pharmaceuticals, Inc. Class A

Amneal Pharmaceuticals, Inc. Class A

AMRX

0.00
  • Amneal disclosed new interim Phase 4 ELEVATE-PD data on CREXONT in Parkinson’s disease, presented June 5, 2026 at ATRMD 2026.
  • Six-week results across 214 patients showed more daily “Good On” time, less “Off” time, improved motor control following switches from prior oral therapies.
  • Patients moving from RYTARY saw longer uninterrupted symptom-control periods, supporting CREXONT’s positioning as a differentiated extended-release option.
  • Adverse events were mostly mild to moderate, broadly consistent with carbidopa/levodopa therapy, led by dizziness, falls, nausea, dyskinesia.
  • Enrollment is complete; longer-term outcomes from the 12-month follow-up are scheduled for release later in 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606050800PRIMZONEFULLFEED9732237) on June 05, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.